331 related articles for article (PubMed ID: 23652586)
1. Assessing DcR3 expression in relation to survivin and other prognostic factors in B cell non-Hodgkin's lymphoma.
Bedewy AM; Elgammal MM; Bedewy MM; El-Maghraby SM
Ann Hematol; 2013 Oct; 92(10):1359-67. PubMed ID: 23652586
[TBL] [Abstract][Full Text] [Related]
2. Expression of a soluble decoy receptor 3 in patients with diffuse large B-cell lymphoma predicts clinical outcome.
Chang PM; Chen PM; Hsieh SL; Tzeng CH; Liu JH; Chiou TJ; Wang WS; Yen CC; Gau JP; Yang MH
Int J Oncol; 2008 Sep; 33(3):549-54. PubMed ID: 18695885
[TBL] [Abstract][Full Text] [Related]
3. Survivin expression in lymph nodes, affected by lymphoma and reactive hyperplasia.
Mazur G; Haloń A; Wróbel T; Urbaniak J; Kuliczkowski K; Woźniak M
Rocz Akad Med Bialymst; 2004; 49 Suppl 1():76-8. PubMed ID: 15638381
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of EBV-LMP1 and VEGF-A expressions in non-Hodgkin's lymphomas.
Paydas S; Ergin M; Erdogan S; Seydaoglu G
Leuk Res; 2008 Sep; 32(9):1424-30. PubMed ID: 18282597
[TBL] [Abstract][Full Text] [Related]
5. B cell non-Hodgkin's lymphoma: experience from a tertiary care cancer center.
Prakash G; Sharma A; Raina V; Kumar L; Sharma MC; Mohanti BK
Ann Hematol; 2012 Oct; 91(10):1603-11. PubMed ID: 22584851
[TBL] [Abstract][Full Text] [Related]
6. [A study on the expression of myeloid cell leukemia 1 proteins and survivin and their relation with B cell apoptosis in non-Hodgkin's lymphoma].
Zuo XL; Zhou X; Meng J; Zhang KJ; Liu XH; Yang HQ
Zhonghua Nei Ke Za Zhi; 2006 Feb; 45(2):133-5. PubMed ID: 16624124
[TBL] [Abstract][Full Text] [Related]
7. Serum-soluble tumor necrosis factor receptor 2 (sTNF-R2) level determines clinical outcome in patients with aggressive non-Hodgkin's lymphoma.
Goto N; Tsurumi H; Takemura M; Hara T; Sawada M; Kasahara S; Kanemura N; Yamada T; Shimizu M; Takahashi T; Tomita E; Seishima M; Takami T; Moriwaki H
Eur J Haematol; 2006 Sep; 77(3):217-25. PubMed ID: 16856931
[TBL] [Abstract][Full Text] [Related]
8. Expression of the NF-kappaB targets BCL2 and BIRC5/Survivin characterizes small B-cell and aggressive B-cell lymphomas, respectively.
Tracey L; Pérez-Rosado A; Artiga MJ; Camacho FI; Rodríguez A; Martínez N; Ruiz-Ballesteros E; Mollejo M; Martinez B; Cuadros M; Garcia JF; Lawler M; Piris MA
J Pathol; 2005 Jun; 206(2):123-34. PubMed ID: 15880597
[TBL] [Abstract][Full Text] [Related]
9. [Expression of survivin and P63 protein in B cell non-Hodgkin's lymphoma and their effects on cell apoptosis and proliferation].
Zuo XL; Zhou Y; Zhou X; Liu XH; Zhang KJ; Yang HQ; Meng J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Feb; 15(1):99-102. PubMed ID: 17490531
[TBL] [Abstract][Full Text] [Related]
10. Relationship between expression of genes involved in cell cycle control and apoptosis in diffuse large B cell lymphoma: a preferential survivin-cyclin B link.
Kuttler F; Valnet-Rabier MB; Angonin R; Ferrand C; Deconinck E; Mougin C; Cahn JY; Fest T
Leukemia; 2002 Apr; 16(4):726-35. PubMed ID: 11960356
[TBL] [Abstract][Full Text] [Related]
11. Thrombospondin-1 (TSP-1) and Survivin (S) expression in non-Hogkin's lymphomas.
Paydas S; Ergin M; Erdogan S; Seydaoglu G; Yavuz S; Disel U
Leuk Res; 2008 Feb; 32(2):243-50. PubMed ID: 17706282
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of Fas (CD95/APO-1) positivity in patients with primary nodal diffuse large B-cell lymphoma.
Eser B; Sari I; Canoz O; Altuntas F; Cakmak E; Ozturk A; Ozkan M; Er O; Cetin M; Unal A
Am J Hematol; 2006 May; 81(5):307-14. PubMed ID: 16628716
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of CD44v6 in diffuse large B-cell lymphoma.
Inagaki H; Banno S; Wakita A; Ueda R; Eimoto T
Mod Pathol; 1999 May; 12(5):546-52. PubMed ID: 10349995
[TBL] [Abstract][Full Text] [Related]
14. A new subtype-specific monoclonal antibody for IAP-survivin identifies high-risk patients with diffuse large B-cell lymphoma and improves the prognostic value of bcl-2.
Mainou-Fowler T; Overman LM; Dignum H; Wood K; Crosier S; Angus B; Proctor SJ; Anderson JJ
Int J Oncol; 2008 Jan; 32(1):59-68. PubMed ID: 18097543
[TBL] [Abstract][Full Text] [Related]
15. [Apoptosis-antagonizing protein Bcl-2 expression, distribution in non-Hodgkin's lymphoma and its clinical significance].
Chen X; Huang G; Wang W
Zhonghua Zhong Liu Za Zhi; 1997 Mar; 19(2):140-2. PubMed ID: 10743081
[TBL] [Abstract][Full Text] [Related]
16. [Cytogenetic and clinical study on 126 cases of B cell non-Hodgkin's lymphoma with bone marrow involvement].
An G; Zhang JW; Shi LH; Yi SH; Zhao YZ; Qi JY; Zou DH; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2011 Jan; 32(1):34-7. PubMed ID: 21429399
[TBL] [Abstract][Full Text] [Related]
17. Role and prognostic significance of the Ki-67 index in non-Hodgkin's lymphoma.
Broyde A; Boycov O; Strenov Y; Okon E; Shpilberg O; Bairey O
Am J Hematol; 2009 Jun; 84(6):338-43. PubMed ID: 19384938
[TBL] [Abstract][Full Text] [Related]
18. Effect of interleukin-10 gene polymorphisms on clinical outcome of patients with aggressive non-Hodgkin's lymphoma: an exploratory study.
Kube D; Hua TD; von Bonin F; Schoof N; Zeynalova S; Klöss M; Gocht D; Potthoff B; Tzvetkov M; Brockmöller J; Löffler M; Pfreundschuh M; Trümper L
Clin Cancer Res; 2008 Jun; 14(12):3777-84. PubMed ID: 18559596
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinase 9 is a prognostic factor in patients with non-Hodgkin lymphoma.
Sakata K; Satoh M; Someya M; Asanuma H; Nagakura H; Oouchi A; Nakata K; Kogawa K; Koito K; Hareyama M; Himi T
Cancer; 2004 Jan; 100(2):356-65. PubMed ID: 14716772
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
